Compare EME & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EME | ALC |
|---|---|---|
| Founded | 1987 | 1945 |
| Country | United States | Switzerland |
| Employees | 25000 | N/A |
| Industry | Engineering & Construction | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0B | 32.4B |
| IPO Year | 1994 | 2002 |
| Metric | EME | ALC |
|---|---|---|
| Price | $805.78 | $74.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $831.67 | $89.38 |
| AVG Volume (30 Days) | 389.4K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | 0.19% | ★ 0.25% |
| EPS Growth | ★ 30.99 | N/A |
| EPS | ★ 15.89 | N/A |
| Revenue | ★ $16,986,422,000.00 | N/A |
| Revenue This Year | $7.85 | $7.99 |
| Revenue Next Year | $7.05 | $6.38 |
| P/E Ratio | $51.89 | ★ $38.31 |
| Revenue Growth | ★ 16.62 | N/A |
| 52 Week Low | $564.92 | $61.84 |
| 52 Week High | $951.96 | $87.64 |
| Indicator | EME | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 61.40 |
| Support Level | $771.21 | $72.60 |
| Resistance Level | $837.50 | $76.27 |
| Average True Range (ATR) | 26.63 | 1.35 |
| MACD | 3.93 | 0.19 |
| Stochastic Oscillator | 42.80 | 75.44 |
EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.